CRISPR and Cancer

In this clinical update, we look at four ongoing clinical trials involving a gene-edited therapeutic candidate for the treatment of solid cancers.

Caribou Biosciences has reported new 12-month clinical data from its ongoing ANTLER Phase 1 trial of CB-010 for relapsed/refractory B cell non-Hodgkin...

Last week, PACT Pharma shared results from the first clinical trial using CRISPR to direct patients’ immune cells to treat solid tumours. The...

In this post, we introduce our CMN disease overview, which will provide information on all the diseases that are targeted by gene-editing therapies...

Extended survival times and inhibited growth of patient-derived glioblastoma brain tumours have been achieved in mice with CRISPR-Cas9 mediated...

Caribou Biosciences recently shared positive clinical data for its CRISPR-edited CAR-T cell therapy, CB-010, in patients with relapsed/refractory B...

Researchers from Italy’s Ospedale San Raffaele Scientific Institute, in collaboration with Intellia Therapeutics, have used CRISPR to introduce...

This week's clinical update includes news from Allogene Therapeutics and Graphite Bio. The U.S. Food and Drug Administration (FDA) recently granted...